Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALAVE: Talazoparib and Avelumab in Advanced Breast Cancer
NCT03964532Phase 2Active, not recruiting
- Sponsor
- Georgetown University
- Start
- Apr 2019
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib, avelumab in breast cancer, sponsored by Georgetown University. Started Apr 2019; status: active, not recruiting.
02
Drugs
talazoparibavelumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03964532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964532.